Danaher Corp. (DHR): Price and Financial Metrics

Danaher Corp. (DHR): $248.37

1.26 (-0.50%)

POWR Rating

Component Grades

Momentum

D

Stability

B

Sentiment

Quality

B

DHR Price/Volume Stats

Current price $248.37 52-week high $283.63
Prev. close $249.63 52-week low $221.22
Day low $248.08 Volume 2,755,500
Day high $251.65 Avg. volume 2,855,502
50-day MA $254.33 Dividend yield 0.42%
200-day MA $250.49 Market Cap 183.38B

DHR Stock Price Chart Interactive Chart >

DHR POWR Grades

  • Quality is the dimension where DHR ranks best; there it ranks ahead of 83.61% of US stocks.
  • The strongest trend for DHR is in Growth, which has been heading down over the past 155 days.
  • DHR's current lowest rank is in the Momentum metric (where it is better than 13.93% of US stocks).

DHR Stock Summary

  • DANAHER CORP's market capitalization of $187,371,615,970 is ahead of 99.05% of US-listed equities.
  • DANAHER CORP's stock had its IPO on November 5, 1987, making it an older stock than 91.15% of US equities in our set.
  • In terms of volatility of its share price, DHR is more volatile than only 5.72% of stocks we're observing.
  • Stocks that are quantitatively similar to DHR, based on their financial statements, market capitalization, and price volatility, are TMO, ABT, SHEL, CMCSA, and IBM.
  • DHR's SEC filings can be seen here. And to visit DANAHER CORP's official web site, go to www.danaher.com.

DHR Valuation Summary

  • DHR's price/earnings ratio is 29.8; this is 9.36% higher than that of the median Healthcare stock.
  • DHR's price/earnings ratio has moved up 7.5 over the prior 243 months.

Below are key valuation metrics over time for DHR.

Stock Date P/S P/B P/E EV/EBIT
DHR 2023-09-18 6.2 3.6 29.8 26.3
DHR 2023-09-15 6.2 3.6 29.9 26.4
DHR 2023-09-14 6.2 3.6 29.7 26.3
DHR 2023-09-13 6.1 3.6 29.6 26.2
DHR 2023-09-12 6.0 3.5 29.1 25.8
DHR 2023-09-11 6.1 3.6 29.3 25.9

DHR Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at 107.88%.
  • Its year over year price growth rate is now at 10.01%.
  • The 3 year cash and equivalents growth rate now stands at -4.94%.
Over the past 34 months, DHR's revenue has gone up $14,096,700,000.

The table below shows DHR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 31,471 8,519 7,103
2022-09-30 31,250 8,311 6,640
2022-06-30 30,816 8,335 6,206
2022-03-31 30,283 8,455 6,292
2021-12-31 29,453 8,358 6,269
2021-09-30 28,065.3 8,246.3 5,721.4

DHR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DHR has a Quality Grade of C, ranking ahead of 42.27% of graded US stocks.
  • DHR's asset turnover comes in at 0.36 -- ranking 56th of 75 Measuring and Control Equipment stocks.
  • IIVI, COHR, and INTT are the stocks whose asset turnover ratios are most correlated with DHR.

The table below shows DHR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-10-01 0.360 0.604 0.259
2021-07-02 0.353 0.592 0.255
2021-04-02 0.335 0.576 0.221
2020-12-31 0.308 0.560 0.168
2020-10-02 0.267 0.550 0.164
2020-07-03 0.266 0.553 0.164

DHR Price Target

For more insight on analysts targets of DHR, see our DHR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $334.69 Average Broker Recommendation 1.43 (Moderate Buy)

Danaher Corp. (DHR) Company Bio


Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are "Life Sciences", "Diagnostics", and "Environmental & Applied Solutions". (Source:Wikipedia)


DHR Latest News Stream


Event/Time News Detail
Loading, please wait...

DHR Latest Social Stream


Loading social stream, please wait...

View Full DHR Social Stream

Latest DHR News From Around the Web

Below are the latest news stories about DANAHER CORP that investors may wish to consider to help them evaluate DHR as an investment opportunity.

Danaher to Provide Cepheid's Tuberculosis Test to the Global Fund at Cost

Danaher Corporation (NYSE: DHR) ("Danaher"), a global science and technology innovator, today announced it will provide Cepheid's Xpert® MTB/RIF Ultra diagnostic test cartridges for tuberculosis (TB) at Cepheid's cost of $7.97 each to the Global Fund to Fight AIDS, TB and Malaria ("the Global Fund") and to less-developed countries eligible for Cepheid's Global Access Program1 to support greater access to high-quality TB testing. The Global Fund is the largest provider of financing and programs t

Yahoo | September 19, 2023

Danaher (DHR) Stock Sinks As Market Gains: What You Should Know

Danaher (DHR) closed the most recent trading day at $253.77, moving -0.58% from the previous trading session.

Yahoo | September 18, 2023

17 Best Low Risk Investments in 2023

In this article, we will take a look at the 16 best low risk investments in 2023. To see more such companies, go directly to 5 Best Low Risk Investments in 2023. Investors are still in a wait and see mode after the latest inflation and retail sales report which give mixed signals. Some analysts […]

Yahoo | September 17, 2023

The 7 Most Undervalued Safe Stocks to Buy in September 2023

Undervalued stocks are in demand as September tends to be a bad market month.

Jeremy Flint on InvestorPlace | September 14, 2023

Abcam founder to vote against proposed $5.7bn acquisition by US Danaher

The founder of UK life sciences company Abcam plans to vote against a proposed $5.7bn acquisition by US group Danaher, pushing instead to replace the board and take back the reins as chief executive. Jonathan Milner, who has a 6.1 per cent stake in the Cambridge-based company, argues the $24-a-share deal materially undervalues Abcam, which creates custom antibodies, among other products, for scientists to use in research. Shares in Abcam were trading at $23.36 before the deal was announced in late August, having risen about 40 per cent after Milner launched a campaign for changes on the board in late May.

Yahoo | September 14, 2023

Read More 'DHR' Stories Here

DHR Price Returns

1-mo -2.55%
3-mo 4.40%
6-mo 0.31%
1-year -6.39%
3-year 21.20%
5-year 134.71%
YTD -6.21%
2022 -19.02%
2021 48.57%
2020 45.34%
2019 49.55%
2018 11.80%

DHR Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full DHR Dividend History

Continue Researching DHR

Want to see what other sources are saying about Danaher Corp's financials and stock price? Try the links below:

Danaher Corp (DHR) Stock Price | Nasdaq
Danaher Corp (DHR) Stock Quote, History and News - Yahoo Finance
Danaher Corp (DHR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!